Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11Head & Neck 1Gynecologic 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cisplatin 28toripalimab 14Radiotherapy 12Gemcitabine 12Capecitabine 11Radiotherapy, Intensity-Modulated 10pembrolizumab 9Surgical Procedures, Operative 9Docetaxel 9tislelizumab 8Carboplatin 7Drug Therapy 6Blood Specimen Collection 6anlotinib 5Taxes 5Paclitaxel 5Nivolumab 5Fluorouracil 5Cetuximab 5130-nm albumin-bound paclitaxel 5Thyroxine 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4trametinib 3sintilimab 3camrelizumab 3Radiation 3Observation 3Injections 3Immune Checkpoint Inhibitors 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × dalpiciclib × Head & Neck × Clear all
NCT06199271 2024-01-22

Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma

Sichuan University

Phase 2 Not yet recruiting
30 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡